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Abstract Background & Aims: Mutations in TP53, a tumor sup-
pressor gene, are associated with prognosis of many cancers. How-
ever, the prognostic values of TP53 mutation sites are not known
for patients with hepatocellular carcinoma (HCC) because of hetero-
geneity in their geographic and etiologic backgrounds.
Methods: TP53 mutations were investigated in a total of 409 HCC
patients, including Chinese (n = 336) and white (n = 73) patients,
using the direct sequencing method.
Results: A total of 125 TP53mutations were found in Chinese patients
with HCC (37.2%). HCC patients with TP53 mutations had a shorter
overall survival time compared with patients with wild-type TP53
(hazard ratio [HR], 1.86; 95% conﬁdence interval [CI]: 1.37–2.52;
P < .001). The hot spot mutations R249S and V157F were signiﬁcantly
associated with worse prognosis in univariate (HR, 2.11; 95% CI:
1.51–2.94; P < .001) and multivariate analyses (HR, 1.79; 95% CI:
1.29–2.51; P < .001). Gene expression analysis revealed the existence
of stem cell-like traits in tumors with TP53 mutations. These ﬁndings
were validated in breast and lung tumor sampleswith TP53mutations.
Conclusions: TP53 mutations, particularly the hot spot mutations
R249S andV157F, are associatedwith poor prognosis for patientswith
HCC. The acquisition of stem cell-like gene expression traits might
contribute to the aggressive behavior of tumors with TP53 mutation.
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tumor suppressor gene (TSG). TP53 functions as a master check-TP53 is recognized as the ‘guardian of the genome’ [1]. It was
point during cell division. It induces cell arrest when detecting
DNA damage, and if it is not corrected, it promotes apoptosis.
TP53 is the most frequently mutated TSG in human cancers [2].
Despite the robust evidence linking loss of TP53 function and
cancer, there is not a single FDA-approved drug able to restore
its function in human malignancies.
There is a strong association between TP53 mutations and
hepatocellular carcinoma (HCC). According to the Catalog of
Somatic Mutations in Cancer (COSMIC) database, 30% of all HCC
have a mutation in this gene, being ranked ﬁrst in terms of muta-
tion frequency for this disease. Nevertheless, mutation rate is
highly variable among studies, ranging from 0% to 67% [3], being
higher in sub-Saharan Africa and East Asia (except Japan). Expo-
sure to aﬂatoxin B1 (AFB1) was identiﬁed as a clear risk factor to
develop a TP53 mutation in a speciﬁc hotspot (codon 249) [4].
AFB1 in conjunction with hepatitis B virus (HBV) infection justify
the high HCC rates found in these geographical regions. Data from
Western studies are scarce and show lower rates of TP53 muta-
tion (12% [5]). In order to provide a clearer picture of the patho-
genic and prognostic role of TP53 mutations in HCC, Woo et al. [6]
have evaluated the presence of TP53 mutations in the largest
cohort of human HCC ever analyzed for this purposed (n = 409).
The cohort included mostly HCC Chinese patients (80%) with
advanced liver disease (75% cirrhosis) due to HBV infection trea-
ted with surgical resection. Results conﬁrm an overall TP53
mutation rate (exon 5–8) of 33%, but when authors sub-analyzed
data according to sample origin, mutation rate signiﬁcantly var-
ied: 37% in Chinese samples versus 7% in HCC fromWestern pop-
ulations (n = 71, Belgium and US). There is a debate whether TP53
mutations are initiating or late events in hepatocarcinogenesis,
since they are usually seen in advanced stages and larger tumors
[7]. It is also possible that rare clones harboring TP53 mutations
are present already at the time of tumor initiation but went
undetected by conventional capillary sequencing. The application
of next-generation sequencing techniques with deeper coverage
in HCC will be extremely valuable to conﬁrm this possibility.
Mutations were mostly located in two hotspots (R249S and
V157F), regardless of sample origin. Interestingly, patients with
TP53 mutations had signiﬁcantly worse prognosis, and when
compared with other clinico-pathological variables, hotspot11 vol. 55 j 724–725
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Fig. 1. There is a clear association between aﬂatoxin B1 exposure, hepatitis B
infection, and TP53 mutated HCC. Hotspot mutations in TP53 are also enriched
in tumors harboring the hepatoblast signature, a genomic feature that suggests
tumor progenitor cell origin. Data on hepatitis C suggest a less strong association.
JOURNAL OF HEPATOLOGYTP53 mutations were identiﬁed as an independent predictor of
survival. Compliance with REMARK guidelines [8] including
external validation in a wider variety of HCC patients (e.g., HCV
etiology) [9], will be necessary prior to the inclusion of TP53
mutations in clinical management guidelines as a prognostic pre-
dictor in HCC.
Worldwide, there are two main epidemiological types of
human HCC, located in different geographical areas and due to
distinct etiological factors. One is associated to HBV infection
and not always develops on patients with advanced liver disease.
Conversely, the second is linked to hepatitis C, and it almost uni-
versally develops in cirrhotic livers. Few studies have thoroughly
dissected the molecular differences between both. Data regarding
TP53 mutations provides a molecular hint about possible back-
ground differences between them. The study by Woo et al. [6]
found a signiﬁcant enrichment of stem cell-like genomic traits
in samples with TP53mutations, providing a potential pathogenic
link between loss of TP53 function and impaired cell reprogram-
ing. Elevation of AFP serum levels is common in patients with
advanced HCC, regardless of background etiology, what could
also suggest the acquisition of a stem-cell like phenotype as
tumor progresses. These stem cell-like signatures have been
shown to confer poor prognosis in Eastern HCC cohorts [10],
although data have not yet been validated in early-stage
HCC patients from the West [11]. In non-HBV HCC and
despite its lower incidence, data suggest a link between TP53
mutations and signatures also associated with poor prognosisJournal of Hepatology 201(e.g. G3-proliferation class [11,12], Fig. 1). The question still
remains why TP53 mutations are signiﬁcantly more prevalent in
Eastern cohorts, and if this is a result of a clear-cut molecular
HCC subtype related to underlying etiology (e.g., HBV and AFB1
exposure), or it is just amolecular event thatbecomesmoreevident
asHCCprogresses. The fact thatHCC isdiagnosedatmoreadvanced
stages in Eastern populations makes this discrimination more dif-
ﬁcult. It could be that TP53 loss determines a switch in tumor cell
genomic proﬁling regardless when it happens during HCC evolu-
tion. Validation of these hypotheses using experimental models
will be of great value. Overall, the study by Woo et al. [6] provide
evidence supporting the role of TP53 inactivation in HCC progres-
sion by connecting it with aggressive biological behavior repre-
sented by stem-like signature and poor survival.Conﬂict of interest
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